Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell
Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:
- Cell line generation for bio-production and bioassays
- Patient-relevant cell models for personalized medicine
- Physiologically predictive animal and cellular models of human disease
Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.
ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]
Bio-Techne Files Drug Master File For ExCellerate GMP iPSC Expansion Medium to Support Manufacture of Stem Cell Therapies
MINNEAPOLIS, MN, December 20, 2023 — Bio-Techne Corporation (NASDAQ: TECH) has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies. [Read more…]
iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.
Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]
Century Therapeutics Progressing CNTY-101, its iPSC-derived CAR NK Cell Candidate, Into a Phase 1 Trial
Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication
Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024
CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 78
- Next Page »